Key Stats for Corteva Stock
- Past-Week Performance: -2.4%
- 52-Week Range: $53.4 to $82.3
- Current Price: $82
What Happened?
Corteva (CTVA), an agriscience company selling seed technology and crop protection chemicals to farmers worldwide, just settled a decade-defining legal dispute with Bayer that accelerates its corn out-licensing business by five years and opens the U.S. cotton market for the first time, all while the stock trades near its 52-week high of $82.26.
On February 3, Corteva paid $610 million to resolve all outstanding litigation with Bayer, unlocking freedom to license its proprietary triple-stack corn traits as early as 2027 and entering U.S. cotton licensing, a market it previously had no access to, with projected aggregate earnings upside of $1 billion over the next decade.
Underpinning that licensing expansion, Corteva’s seed royalty position swung from a net expense of roughly $700 million five years ago to neutrality in 2026, two years ahead of schedule, while FY2025 free cash flow hit a record $2.9 billion, a conversion rate exceeding 75% of operating EBITDA that peers in the agricultural chemicals sector have rarely matched.
A confirmed near-term catalyst sharpens the forward case: Haviza, Corteva’s fungicide targeting Asian soybean rust in Brazil, the world’s largest soybean market, is expected to receive regulatory approval in 2026 and has been described by management as a blockbuster product.
Furthermore, Chuck Magro, Chief Executive Officer, stated on the Q4 2025 earnings call that “over the course of the next 10 years, we believe this agreement will generate about $1 billion of aggregate earnings upside for Corteva across our corn, cotton and canola portfolios through both out-licensing and branded sales,” anchoring the thesis directly to the February Bayer settlement.
Corteva targets separation into two independent publicly traded companies by Q4 2026, with an Investor Day for both entities set for mid-September, $500 million in H1 share repurchases already committed, a $9 billion Crop Protection pipeline, and hybrid wheat launching in the U.S. in 2027, collectively pointing to a multi-year value unlock that the current $82.03 price has only begun to price in.
Wall Street’s Take on CTVA Stock
The Bayer settlement, which clears $610 million in one-time payments in exchange for accelerated corn licensing and a new cotton market, directly converts a decade of litigation cost into a multi-year earnings ramp beginning in 2027.
EBITDA, the operating profit measure that strips out separation noise and one-time items, is projected to expand from $3.9 billion in FY2025 to $4.4 billion by FY2027, with margins widening from 22.1% to 23.5%, driven by the royalty swing and Crop Protection volume recovery that management confirmed at the February 25 BofA conference.
Normalized EPS growth reinforces the margin story: consensus projects $3.66 in FY2026 rising to $4.04 in FY2027 and $4.50 in FY2028, a compounding that reflects the royalty neutrality tailwind and Haviza’s fungicide launch in Brazil, the world’s largest soybean market, landing in the same window.
Fifteen analysts covering CTVA carry a mean price target of $83.48, implying just 1.8% upside from $82.03, with 12 buys, 3 outperforms, and 7 holds and no sells, a distribution that reflects broad conviction on fundamentals but suggests consensus has largely caught up to the pre-Bayer story.
The $27 gap between the $68 analyst floor and the $95 ceiling maps directly onto the two outcomes: bears price in separation execution risk and continued Latin America crop protection pricing pressure, while bulls credit the full corn and cotton licensing ramp beginning 2027.
What Does the Valuation Model Say?
The TIKR mid-case targets $100.7 per share by December 2030, a 22.8% total return at a 4.4% IRR, assuming 2.2% revenue CAGR and net income margins expanding from 13.1% to 15.1%, justified by royalty neutrality in 2026 and the Bayer-accelerated corn out-licensing timeline.
The market is pricing a mature, slow-growth agrichemical company, but the royalty position just swung $700 million in five years with the inflection still accelerating.
Corn out-licensing launching as early as 2027, five years ahead of plan, and Haviza’s pending Brazil approval justify the TIKR model’s $100.70 target directly from confirmed, dated catalysts.
Magro confirmed at the BofA conference that even today, Corteva has more licensing demand than supply, validating that the $1 billion royalty target is demand-constrained, not ambition-constrained.
If Crop Protection pricing pressure in Latin America deepens beyond the low single-digit declines already built into FY2026 guidance, the $4.1 billion EBITDA midpoint breaks and margin expansion stalls.
The mid-September 2026 Investor Day for both separated companies is the single event that will quantify the SpinCo capital structure and licensing revenue targets, the numbers the TIKR model depends on.
Should You Invest in Corteva, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CTVA stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Corteva, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CTVA stock on TIKR for Free →
